We’re pleased to share a new video from our investee company, Laverock Therapeutics.
Hear directly from CEO David Venables and the team as they explain how Laverock is developing a next-generation gene control platform designed to address some of the most challenging diseases, including cancer and autoimmune conditions.
In just a few minutes, you’ll gain insight into:
- The problem Laverock is solving
- Why its technology is differentiated
- Progress to date and the road ahead
- The people driving the business forward
Why is Laverock Therapeutics Different?
No Other Technology Can Control Genes like Laverock’s GeiGS® System. Their GEiGS® technology enables specific genes to be controlled in the right place, at the right time and at the right level. No other technology can do this.
With applications across a $30B market in regenerative medicine growing at 16.8% p.a, this innovative company is poised to transform medicine and biotechnology with their precise control over genetic material.
